RecruitingPHASE1, PHASE2NCT06121297
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Studying Systemic lupus erythematosus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cabaletta Bio
- Principal Investigator
- Medical DirectorCabaletta Bio
- Intervention
- CABA-201(biological)
- Enrollment
- 28 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2024 – 2029
Study locations (23)
- University of California Irvine, Orange, California, United States
- UC Davis Health, Sacramento, California, United States
- Yale University, New Haven, Connecticut, United States
- University of Florida Health, Gainesville, Florida, United States
- Mayo Clinic, Jacksonville, Florida, United States
- Emory University, Atlanta, Georgia, United States
- Northwestern Memorial Hospital, Chicago, Illinois, United States
- The University of Chicago Medical Center, Chicago, Illinois, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- Tufts Medical Center, Boston, Massachusetts, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Brigham and Women's Hospital, Boston, Massachusetts, United States
- UMass Memorial Hospital, Worcester, Massachusetts, United States
- University of Minnesota, Minneapolis, Minnesota, United States
- +8 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06121297 on ClinicalTrials.govOther trials for Systemic lupus erythematosus
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT07107659Safety and Efficacy of ONT01 in LupusHospital for Special Surgery, New York
- RECRUITINGNANCT07558850Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune DiseasesThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGNCT06948110Deciphering the Genetic Architecture of Autoimmune DiseasesNational Human Genome Research Institute (NHGRI)
- RECRUITINGPHASE2NCT07409181A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)Boehringer Ingelheim
- RECRUITINGPHASE3NCT07332481A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic DiseaseEMD Serono Research & Development Institute, Inc.
- RECRUITINGEARLY PHASE1NCT07526350MTS109 in Patients With Refractory Autoimmune DiseasesShanghai Changzheng Hospital
- RECRUITINGEARLY PHASE1NCT07490041Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic DiseasesThe Children's Hospital of Zhejiang University School of Medicine
- RECRUITINGNANCT07470151Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology